These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7560252)

  • 1. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic.
    Sainati SM; Hubbard JW; Chi E; Grasing K; Brecher MB
    J Clin Pharmacol; 1995 Jul; 35(7):713-20. PubMed ID: 7560252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG; Preskorn S; Hochfeld M; Meng X
    J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iloperidone: A new drug for the treatment of schizophrenia.
    Arif SA; Mitchell MM
    Am J Health Syst Pharm; 2011 Feb; 68(4):301-8. PubMed ID: 21289324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iloperidone for the treatment of schizophrenia.
    Marino J; Caballero J
    Ann Pharmacother; 2010 May; 44(5):863-70. PubMed ID: 20388862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of risperidone.
    Ereshefsky L; Lacombe S
    Can J Psychiatry; 1993 Sep; 38 Suppl 3():S80-8. PubMed ID: 7504573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
    Albers LJ; Musenga A; Raggi MA
    Expert Opin Investig Drugs; 2008 Jan; 17(1):61-75. PubMed ID: 18095919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.
    Vanover KE; Robbins-Weilert D; Wilbraham DG; Mant TG; van Kammen DP; Davis RE; Weiner DM
    J Clin Pharmacol; 2007 Jul; 47(7):915-9. PubMed ID: 17495279
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
    Zhu Y; Statkevich P; Cutler DL
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iloperidone: a clinical overview.
    Citrome L
    J Clin Psychiatry; 2011; 72 Suppl 1():19-23. PubMed ID: 22217439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iloperidone for schizophrenia.
    Rado J; Janicak PG
    Expert Opin Pharmacother; 2010 Aug; 11(12):2087-93. PubMed ID: 20586713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iloperidone for the management of adults with schizophrenia.
    Crabtree BL; Montgomery J
    Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
    Cutler AJ; Kalali AH; Mattingly GW; Kunovac J; Meng X
    CNS Spectr; 2013 Feb; 18(1):43-54. PubMed ID: 23312567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.
    Huang ML; Van Peer A; Woestenborghs R; De Coster R; Heykants J; Jansen AA; Zylicz Z; Visscher HW; Jonkman JH
    Clin Pharmacol Ther; 1993 Sep; 54(3):257-68. PubMed ID: 7690693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2010 May; 64(6):707-18. PubMed ID: 20201991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.